ConferencePoster
 (2024)

Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study

Yonemori, K; Rojas, CI; Leary, A; Le Tourneau, C; Lugowska, I; Ozyilkan, O; Caglevic, C; Ghiringhelli, F; Yanez, EP; Dongen, MV; Perets, R; Gumus, M; Kwiatkowski, M; Rha, SY; Salman, P et al.